The assays (primers and probes only) are designed to detect the mutations of human epidermal growth factor in tissue DNA and cfDNA from plasma.
In Asian patients with non-small cell lung cancer, the frequency of EGFR driver gene mutations is approximately 30%, and the frequency of EGFR-19del mutation, which is a drug-sensitive mutation, is approximately 47%.